MFS
KPTI icon

MSI Financial Services’s Karyopharm Therapeutics KPTI Stock Holding History

MSI Financial Services’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$1K Hold
7
– – ﹤0.01% 3675
2016
Q3 		$1K Hold
7
– – ﹤0.01% 3700
2016
Q2 		$1K Buy
+7
New +$909 ﹤0.01% 3722

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MSI Financial Services's KPTI Position: Q4 2016 in Review

MSI Financial Services held its Karyopharm Therapeutics (KPTI) position steady in Q4 2016 at 7 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #3675.

MSI Financial Services first reported a position in KPTI in Q2 2016 and has held it in 3 quarters since. 86 funds tracked by Wall St. Rank hold KPTI as of Q4 2016.

  • MSI Financial Services held 7 shares of Karyopharm Therapeutics worth $1K as of Q4 2016.
  • MSI Financial Services left its Karyopharm Therapeutics share count unchanged in Q4 2016.
  • Karyopharm Therapeutics made up ﹤0.01% of MSI Financial Services's portfolio in Q4 2016, its #3675 holding.
  • MSI Financial Services first reported a position in Karyopharm Therapeutics in Q2 2016 and has held it in 3 quarters since.
  • 86 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2016.

Based on MSI Financial Services's 13F filing for Q4 2016, filed 13 Jan 2017.